A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: The SYNTAX trial at 3 years

  • Patrick W. Serruys
  • , Vasim Farooq
  • , Pascal Vranckx
  • , Chrysafios Girasis
  • , Salvatore Brugaletta
  • , Hector M. Garcia-Garcia
  • , David R. Holmes
  • , Arie Pieter Kappetein
  • , Michael J. Mack
  • , Ted Feldman
  • , Marie Claude Morice
  • , Elisabeth Ståhle
  • , Stefan James
  • , Antonio Colombo
  • , Peggy Pereda
  • , Jian Huang
  • , Marie Angèle Morel
  • , Gerrit Anne Van Es
  • , Keith D. Dawkins
  • , Friedrich W. Mohr
  • Ewout W. Steyerberg

Research output: Contribution to a Journal (Peer & Non Peer)Articlepeer-review

94 Citations (Scopus)

Abstract

Objectives: The aim of this study was to assess the additional value of the Global Risk - a combination of the SYNTAX Score (SXscore) and additive EuroSCORE - in the identification of a low-risk population, who could safely and efficaciously be treated with coronary artery bypass graft surgery (CABG) or percutaneous coronary intervention (PCI). Background: PCI is increasingly acceptable in appropriately selected patients with left main stem or 3-vessel coronary artery disease. Methods: Within the SYNTAX Trial (Synergy between PCI with TAXUS and Cardiac Surgery Trial), all-cause death and major adverse cardiac and cerebrovascular events (MACCE) were analyzed at 36 months in low (GRC LOW) to high Global Risk groups, with Kaplan-Meier, log-rank, and Cox regression analyses. Results: Within the randomized left main stem population (n = 701), comparisons between GRCLOW groups demonstrated a significantly lower mortality with PCI compared with CABG (CABG: 7.5%, PCI: 1.2%, hazard ratio [HR]: 0.16, 95% confidence interval [CI]: 0.03 to 0.70, p = 0.0054) and a trend toward reduced MACCE (CABG: 23.1%, PCI: 15.8%, HR: 0.64, 95% CI: 0.39 to 1.07, p = 0.088). Similar analyses within the randomized 3-vessel disease population (n = 1,088) demonstrated no statistically significant differences in mortality (CABG: 5.2%, PCI: 5.8%, HR: 1.14, 95% CI: 0.57 to 2.30, p = 0.71) or MACCE (CABG: 19.0%, PCI: 24.7%, HR: 1.35, 95% CI: 0.95 to 1.92, p = 0.10). Risk-model performance and reclassification analyses demonstrated that the EuroSCORE--with the added incremental benefit of the SXscore to form the Global Risk--enhanced the risk stratification of all PCI patients. Conclusions: In comparison with the SXscore, the Global Risk, with a simple treatment algorithm, substantially enhances the identification of low-risk patients who could safely and efficaciously be treated with CABG or PCI.

Original languageEnglish
Pages (from-to)606-617
Number of pages12
JournalJACC: Cardiovascular Interventions
Volume5
Issue number6
DOIs
Publication statusPublished - Jun 2012
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • 3-vessel disease
  • Global Risk
  • left main disease
  • SYNTAX Score

Fingerprint

Dive into the research topics of 'A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: The SYNTAX trial at 3 years'. Together they form a unique fingerprint.

Cite this